A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ELOQUENT-1
- Sponsors Bristol-Myers Squibb
- 29 Mar 2017 Planned End Date changed from 1 Jul 2019 to 1 Jan 2019.
- 12 Apr 2016 Planned End Date changed from 1 Jul 2020 to 1 Jul 2019.
- 08 Feb 2015 Planned primary completion date changed from 1 May 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov